Generated by AI
X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system and rare hematology disorders. The company’s core work centers on CXCR4-targeted medicines, including mavorixafor, an oral small-molecule antagonist designed to improve immune cell trafficking and address conditions marked by chronic neutropenia and immunodeficiency. X4 Pharmaceuticals markets XOLREMDI in the United States and continues to evaluate mavorixafor in additional indications through clinical development programs. Its portfolio and commercial activity place it at the intersection of immunology, hematology, and rare-disease care, serving patients with significant unmet medical needs. Based in Boston, Massachusetts, X4 Pharmaceuticals plays a specialized role in the biotechnology market by focusing on treatments for underserved patient populations.
Website61 North Beacon Street
Boston, MA, 02134
United States
The latest articles about XFOR.
Summary of Jul 23's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Investors talking about XFOR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.